Last edition
News about Market
Merck Ends Acquisition Talks With Revolution Medicines
Merck has ended discussions to acquire cancer drug developer Revolution Medicines after the two sides failed to agree on valuation, according to reports. The talks, which had been ongoing for several weeks, were discontinued as differences over pricing could not be resolved.
Market | 27/01/2026 | By Darshana | 186
Mair Therapeutics and Radboud University Partner to Advance Parkinson's Therapy
Mair Therapeutics has entered into a scientific collaboration with Radboud University to advance the development of TMEM175 agonists for Parkinson’s disease, with Dr Marijn Kuijpers’ laboratory at the Donders Centre for Neuroscience evaluating a portfolio of TMEM175-targeting compounds developed by the company.
Market | 27/01/2026 | By News Bureau | 271
Syngene International reported a muted financial performance for the third quarter of FY26, with consolidated revenue declining three percent year on year to INR nine hundred thirty two crore, compared with INR nine hundred sixty two crore in the same quarter last year. Profit after tax, before exceptional items, stood at INR seventy three crore.
Market | 23/01/2026 | By Darshana | 586
Dr Reddy's Q3 FY26 Net Profit Falls Fourteen Percent Despite Revenue Growth
Dr Reddy’s Laboratories reported consolidated revenue of INR eight thousand seven hundred twenty seven crore in the third quarter of financial year twenty six, registering year on year growth.
Market | 23/01/2026 | By Darshana | 359
Zydus Launches World's First Nivolumab Biosimilar 'Tishtha' in India
Zydus Lifesciences has launched Tishtha, the world’s first biosimilar of the immunotherapy drug nivolumab, in India, aimed at expanding access to advanced cancer care by offering the treatment at nearly one-fourth the cost of the reference product for patients with multiple cancer types.
Market | 23/01/2026 | By News Bureau | 1205
G Square Backs Serres in Majority Acquisition to Drive Global Growth
G Square, a European healthcare-focused private equity firm investing in high-growth mid-market companies, has signed an agreement to acquire a majority stake in Serres, a global leader in sustainable surgical fluid management solutions.
Market | 21/01/2026 | By Darshana | 319
Lupin Partners with Galenicum to Commercialise Injectable Semaglutide
Global pharmaceutical major Lupin Limited has entered into a licensing and supply agreement with Galenicum Health, S.L.U. through its subsidiary, Lupin Atlantis Holdings SA (LAHSA), for finished injectable formulations of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist.
Market | 21/01/2026 | By Darshana | 438
Infinitopes Raises USD 35.1 Million to Advance Precision Cancer Vaccine into First-in-Human Trial
Infinitopes, a clinical-stage biotechnology company developing cancer vaccines, has completed the second close of its seed financing round, raising an additional USD 15.4 million and bringing total funds secured to USD 35.1 million.
Market | 21/01/2026 | By Darshana | 270
Bayer and VUMC Partner to Advance Cardiovascular and Kidney Therapies
The collaboration will focus initially on cardiovascular and kidney diseases, combining Bayer’s drug development expertise with Vanderbilt University Medical Center’s extensive data resources to generate data-driven insights and accelerate the discovery and development of new therapies addressing significant unmet medical needs.
Market | 21/01/2026 | By News Bureau | 253
Insilico Medicine and Hygtia Therapeutics have entered a co-development deal for ISM8969, an AI-designed, brain-penetrant NLRP3 inhibitor, with milestone payments of up to USD 66 million.
Market | 21/01/2026 | By News Bureau | 323
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy